



MVIP

MEDICON VILLAGE
INVESTOR PANEL

**AUTUMN
BATCH 2026**

STRATEGIC CAPITAL. EXPERT GUIDANCE. LIFE-CHANGING LIFE SCIENCE.

MVIP

The Medicon Village Investor Panel (MVIP) is a strategic initiative by Medicon Village designed to strengthen the financial ecosystem for life science companies by connecting them with crucial capital and expert investor support.



Medicon Village is Scandinavia's largest life science park. We're here to foster innovation and advance collaboration to support your research and business.

Medicon Village encompasses the entire life science spectrum, from research in key fields such as biotech, pharma, and medtech to members specialising in the full healthcare chain – from prevention and diagnostics to treatment and care. Together, Medicon Village provides most of the services and equipment needed for life science research and business, including pre-clinical and biobank facilities, either on-site or within walking distance in the Lund Innovation District.



A word from Medicon Village

Access to capital remains one of the most pressing challenges for growing life science companies. In a sector where development is complex and capital-intensive, strong investor relationships are essential – not only for securing funding, but also for gaining strategic insights, expertise and access to critical networks.

Following a successful inaugural edition in 2025, we are pleased to bring back the Medicon Village Investor Panel (MVIP) for a second year. Developed in collaboration with Markus Neuding, corporate finance expert and owner of Sedermera Corporate Finance, MVIP provides companies with a structured platform to strengthen their investment readiness and engage directly with experienced life science investors.

What sets MVIP apart is its long-term approach. Rather than focusing solely on individual funding rounds, the initiative helps companies prepare for sustainable growth through actionable feedback and relationships with investors across different capital stages.

The first edition demonstrated the value of this approach, creating high-quality dialogue and new connections between participating companies and investors. In 2026, we look forward to building on that foundation and further strengthening the connections between promising life science companies and relevant capital.

At Medicon Village, we are committed to supporting companies throughout their growth journey. MVIP is an important part of that commitment and our ambition to contribute to a stronger, better connected and well-funded life science ecosystem.



Petter Hartman, CEO
Medicon Village Innovation



Sarah Lidé, Deputy CEO
Medicon Village Innovation

About MVIP

Medicon Village Investor Panel (MVIP) is a strategic initiative designed to strengthen the financial ecosystem for life science companies by connecting them with crucial capital and expert investor support.

This program will connect Medicon Village companies with a curated panel of experienced investors to help accelerate growth and innovation in the life science sector.

Led by corporate finance expert Markus Neuding, MVIP offers a unique opportunity for companies to pitch their businesses to a distinguished panel of investors with diverse backgrounds in life science funding.

By bringing together professionals with diverse experience in life science funding, MVIP will provide access to new capital and unlock valuable expertise, strategic insights, and networking opportunities essential for growth and success in this complex sector.

MVIP

The team behind MVIP



Markus Neuding Owner, Sedermera Corporate Finance

Markus is a former lawyer and seasoned entrepreneur with a background as Executive Vice President of Spotlight Group. He recently acquired Sedermera Corporate Finance, one of the Nordic region's most active advisory firms within capital raising and M&A for growth companies, where he now serves as owner and principal. Markus has founded and built several companies and brings deep expertise in entrepreneurship, business development, and exits. As the coordinator of the Medicon Village Investor Panel, he also serves as a permanent member of the panel.

markus.neuding@sedermera.se



Sarah Lidé Deputy CEO, Medicon Village Innovation

Sarah has two decades' worth of experience in management consulting and ecosystem building within the public sector, healthcare, and life science sectors. She has held a variety of international roles involving leading and facilitating strategic processes, understanding macro and industry trends and their implications for business, and driving multi-stakeholder engagement. In her current position as Deputy CEO at Medicon Village Innovation, she leads various life science-related strategic initiatives on behalf of Medicon Village to support companies in the areas of commercialisation, capital access, and competence supply, including the Medicon Village Investor Panel.

sarah.lide@mediconvillage.se



Francesco Bez Ph.D. Innovation Manager, Medicon Village Innovation

Francesco is Innovation Manager at Medicon Village, where he leads strategic initiatives in the life science sector. He holds a Ph.D. in Neuroscience and Biomedicine and brings a solid background in both preclinical research and marketing. Over the past decade, Francesco has held various roles within Medicon Village-based companies, contributing to their growth and the development of their service offerings. In his current role, he is actively engaged in several EU-funded programs and regional initiatives, as well as strategic collaborations with big pharma companies and investor networks.

francesco.bez@mediconvillage.se



Asgard Therapeutics

BIOTECH



Aventera Antibodies

PHARMA

BIOTECH



Dx4Life

MEDTECH



Gedea Biotech

MEDTECH

BIOTECH



ImmuneBiotech

BIOTECH



Lead Biologics International

PHARMA

BIOTECH



rAAVen Therapeutics

PHARMA

BIOTECH



Xaga Surgical

MEDTECH



PARTICIPATING INVESTORS



Bengt Julander
Linc



Shamim Dadvar
HealthCap



Erika Wallace
J.P. Morgan Private Bank



Emilia Carlqvist
Innovestor



Jonathan P. Gertler
Back Bay Life Science
Advisors



Karin Leire
Segulah Medical
Acceleration



Bitra Sehat
Trill Impact



Arvid Söderhäll
Flerie



Markus Dietric
Hadean Ventures



Jonas Jendi
Industrifonden



PROGRAM

SEPTEMBER 17

08.30–09.00

Welcome & Breakfast

Light breakfast and networking

09.00–09.15

Introduction from Medicon Village

Morning Session: Company Pitches – Part 1

09.15–09.50

Asgard Therapeutics

09.50–10.25

rAAVen Therapeutics

10.25–10.45

Coffee Break & Mingling

10.45–11.20

Dx4Life

11.20–11.55

Gedea Biotech

12.00–13.00

Lunch break

Afternoon Session: Company Pitches – Part 2

13.00–13.35 ImmuneBiotech

13.35–14.10 Lead Biologics

14.10–14.30 **Coffee Break & Mingling**

14.30–15.05 Aventura Antibodies

15.05–15.40 Xaga Surgical

15.40–16.30 **Closing Remarks & Networking**
Final reflections and mingling



Asgard Therapeutics

Asgard Therapeutics is pioneering in vivo direct cell reprogramming for cancer immunotherapy, recreating therapeutic immune cells inside the patient. Its lead program, AT-108, is a first-in-class, off-the-shelf gene therapy that directly reprograms tumor cells into highly immunogenic dendritic cells, kick-starting a systemic and tumor-targeted immune response.

Asgard is in IND-enabling studies, with CTA approval planned for 2027, while expanding its reprogramming platform into systemic RNA/LNP programs and applications beyond oncology.

asgardthx.com

FIELD

Biotech

PRODUCT ON THE MARKET?

No

DATE OF INCORPORATION

2018

AMOUNT THEY WISH TO RAISE WITH MVIP

75 MEuros

STOCK MARKET LISTING

No

HOW THEY INTEND TO USE THE FUNDS RAISED

Bring AT-108 through clinical PoC and build a reprogramming pipeline

MATURITY

Pre-Clinical research



Cristiana Pires, PhD

CEO and co-founder

Cristiana Pires is CEO and co-founder of Asgard Therapeutics. She holds a PharmD from the University of Porto and a PhD in cellular reprogramming from NOVA Medical School, followed by postdoctoral work on dendritic cell reprogramming at the Pereira Lab, Lund University, which laid the groundwork for founding Asgard.

Under her leadership, the company has raised a EUR 30M Series A in 2024 and EUR 6M Seed in 2021 from leading VC investors, alongside non-dilutive funding to advance AT-108 towards FIH trials.

cristiana.pires@asgardthx.com

NOTES



Aventera Antibodies

Aventera Antibodies is a Lund-based biotech developing precision immunotherapies against invasive Group A Streptococcal (GAS) disease. Potential sales exceeding 1 BUSD annually in US alone. The proprietary platform originates from refined antibodies from patients in recovery. The lead program is a first-in-class therapeutic antibody engineered for broad strain coverage and robust immune-mediated bacterial killing.

The lead candidate is scaling towards clinical manufacturing and studies to determine FIH dose. With plans to enter clinical trials by 2028 with trial design to include healthy and sick patients for early signs of efficacy and demonstrate safety. Aventera's approach could significantly improve outcomes for severe streptococcal infections (currently ~30% mortality).

aventeraantibodies.com

FIELD

Pharmaceuticals,
Biotechnology

DATE OF INCORPORATION

2025

STOCK MARKET LISTING

No

MATURITY

Development stage/
Pre-clinical

PRODUCT ON THE MARKET?

No

AMOUNT THEY WISH TO RAISE WITH MVIP

5-10 MEuros

HOW THEY INTEND TO USE THE FUNDS RAISED

To advance our candidate to/through Ph1a+b completion



Arman Izadi, PhD

CEO

Arman Izadi, MD PhD, is founder and CEO of Aventera Antibodies. A licensed physician and physician-scientist trained at Lund University, he has worked clinically and scientifically at both Karolinska Institutet and Lund University, with expertise in infectious disease and antibody engineering.

His doctoral work on a novel antibody subclass targeting streptococci, forms part of the scientific foundation for Aventera's antibody design and was awarded the Anna-Greta Crafoord Prize for best doctoral thesis in 2025.

arman@aventeraantibodies.com



Göran Forsberg

Chairman of the Board

He joined Aventera as Chairman in 2025, drawn by the opportunity to apply a novel antibody engineering technology to treat a disease with 30% mortality and no targeted therapy. PhD in Biochemistry with more than three decades of experience in drug development, including senior roles at Pharmacia and Active Biotech.

Served as CEO of Cantargia for a decade, taking the company from a private preclinical venture to a Nasdaq Stockholm-listed clinical-stage company with two clinical programs. Has raised more than \$200M in capital across his career, and one program was subsequently acquired by Otsuka Pharmaceutical in a transaction valued at up to \$560M (2025).

NOTES



Dx4Life

Dx4Life is a Swedish medtech/diagnostics startup focused on personalized reproductive medicine. Its first product, Dx4IVF, is a genotyping device used in IVF clinics to match women's genetic profiles with the optimal ovarian stimulation hormone.

By quickly analyzing patients' DNA before IVF, Dx4IVF enables clinicians to personalize treatment and significantly improve pregnancy success rates. This approach addresses the high failure rate ($\approx 75\%$ per cycle) of IVF by reducing guesswork in hormone selection.

dx4life.org

FIELD

Medtech

PRODUCT ON THE MARKET?

No

DATE OF INCORPORATION

2024

AMOUNT THEY WISH TO RAISE WITH MVIP

Not disclosed

STOCK MARKET LISTING

No

HOW THEY INTEND TO USE THE FUNDS RAISED

Market expansion

MATURITY

Commercial stage



Yvonne Lundberg Giwercman, PhD

CEO

Professor Yvonne Lundberg Giwercman is CEO of Dx4Life and a reproductive genetics expert. She holds a PhD from Karolinska Institute and was appointed professor at Lund University's Medical Faculty in 2018.

Prof. Lundberg's research on hormonal response genes in IVF patients (published 2025) laid the groundwork for Dx4Life's diagnostic technology. She now brings her scientific and academic experience to commercializing a rapid genetic test for IVF.

yvonne@dx4life.org



Eddie Thordarson

Venture Builder at LU Ventures

Eddie Thordarson is a Sweden-based venture builder and investor with extensive experience in life sciences, biotech, and medtech. He has a strong background in corporate governance, organizational development, strategy, and business growth.

Through his work in the Nordic innovation ecosystem, he focuses on helping organizations scale coherently and effectively. Eddie also brings experience in negotiations, agreements, funding, board work and international business.

NOTES



Gedea Biotech

Gedea Biotech is a Swedish women's health company developing non-antibiotic treatments for vaginal infections. Its lead product, pHyph, is a novel therapy for bacterial vaginosis that bolsters the healthy vaginal microbiome. In clinical trials, pHyph has shown high symptom relief and sustained effect (cure rate of 50-82% by day 7, absence of symptoms <80% by day 14).

The product recently achieved CE-MDR marking, positioning Gedea to launch this antibiotic-free solution in Europe. By targeting the root microbial imbalance, Gedea's approach offers women an effective, safer, long-term treatment option, without the compromises of antibiotics.

gedeabiotech.se

FIELD

Medtech, Medtech and biotech (device in Europe and drug in the US)

DATE OF INCORPORATION

2015

STOCK MARKET LISTING

No

MATURITY

Expansion / Commercial Stage

PRODUCT ON THE MARKET?

No

AMOUNT THEY WISH TO RAISE WITH MVIP

4-6 MEuros

HOW THEY INTEND TO USE THE FUNDS RAISED

Drive partnered commercialization to reach cash positive operations 18 months after launch and accumulated cash positive returns 3 years after launch



Julie Waras Brogren, MBA

CEO

Julie Waras Brogren, MBA, became CEO of Gede Biotech in 2026. She is a veteran biotech leader with over 20 years of experience in pharma, biotech and medtech sectors. Ms. Brogren previously served as Deputy CEO, CCO and CFO at Ascelia Pharma (a Nasdaq-listed orphan oncology company) and was previously President of Canadian medtech company Bresotec.

She also held finance and global launch leadership roles at Novo Nordisk. Julie's core expertise is in product commercialization, business development and raising capital – skills that align with Gede's upcoming commercialization phase.

julie.brogren@gedeabiotech.com

NOTES



ImmuneBiotech

ImmuneBiotech is a Swedish commercial-stage precision microbiome company translating more than 20 years of immunology research into clinically validated, scalable health solutions. Its proprietary ImmuneBiotics® platform combines precision-selected Lactobacillus strains designed to strengthen gut-barrier function and modulate gut-immune-brain pathways.

Lead product GutMagnific® is a clinically validated probiotic food supplement, commercialized in Europe, the US and China. It is supported by completed randomized clinical studies in IBS and post-viral/chronic fatigue.

With proprietary probiotic strains, international regulatory readiness, established manufacturing and growing sales through its own web shop, pharmacies and B2B channels, ImmuneBiotech is positioned to scale revenue while expanding its clinical pipeline.

ImmuneBiotech.com

FIELD

Precision microbiome & probiotics

DATE OF INCORPORATION

2013

STOCK MARKET LISTING

Private company

MATURITY

Commercial stage

PRODUCT ON THE MARKET?

Yes - GutMagnific® and GutMagnific® KiDS revenue-generating probiotic food supplements.

AMOUNT THEY WISH TO RAISE WITH MVIP

0.5 MEuros acceleration + 2.5 MEuros growth

HOW THEY INTEND TO USE THE FUNDS RAISED

Scale inventory; accelerate commercialization in Sweden/EU, the US and China; build the commercial organization for international growth; advance clinical milestones and strategic B2B partnerships



Shahram Lavasani, PhD

Founder & CEO

Immunologist, researcher at Lund University's Faculty of Medicine, and biotech entrepreneur with 20+ years in immunology, inflammation and microbiome/gut-immune-brain research. Brings 15+ years of company building across R&D and CRO leadership, clinical translation, regulatory strategy, fundraising and international commercialization. PhD, Lund University; Fellow of the Royal Society of Medicine (UK); Medicon Village Entrepreneur of the Year 2018; Board Member, International Probiotics Association (IPA).

s.lavasani@immunebiotech.com



Karin Larsson, PhD

CBO & COO

Life-science executive bridging science and business. PhD in Biotechnology and Diploma in Marketing Management from Lund University, with broad probiotic-industry experience spanning programme leadership, strategic dealmaking, procurement, manufacturing and commercial partnerships. Leads cross-functional execution and converts scientific assets into partner-ready offerings, scalable operations and international market opportunities.

k.larsson@immunebiotech.com

NOTES



Lead Biologics International

Lead Biologics is a Swedish biotech focused on developing innovative targeted antibody therapies for cancer. The company leverages recombinant antibody technology to discover novel tumor targets and create first-in-class immune checkpoint and antibody drug candidates.

By combining academic insights with cutting-edge discovery, Lead Biologics aims to revolutionize cancer care with therapies against leukemia, lymphoma and solid tumors. Its research is supported by partnerships with European research networks and the recently announced Nature Cancer publication on a unique checkpoint inhibitor.

leadbiologics.com

FIELD

Pharmaceuticals,
Biotechnology

DATE OF INCORPORATION

2022

STOCK MARKET LISTING

No

MATURITY

Preclinical Research

PRODUCT ON THE MARKET?

No

AMOUNT THEY WISH TO RAISE WITH MVIP

10 MEuros

HOW THEY INTEND TO USE THE FUNDS RAISED

Advance our program to be IND-ready



Anki Malmberg Hager, PhD

CEO

Anki Malmberg Hager, MSc PhD, is a seasoned life-science executive and the CEO of Lead Biologics International AB. She holds advanced degrees in science and business and has over 25 years of biotech leadership experience.

Prior to Lead Biologics, Anki served as CEO of multiple Swedish biotech companies (SenzaGen, PainDrainer, Cantargia, XImmune, Diaprost) and held senior roles in investment and business development at LU Bioscience and Alligator Bioscience. Her core strengths include strategic growth, fundraising, and building cross-functional teams to translate immunotherapy research into commercial products.

ankimhager@leadbiologics.com



Carl Sandén, PhD

Chief Scientific Officer, founder

Senior research scientist at the Division of Clinical Genetics at Lund University with a PhD in experimental hematology and extensive experience in experimental and translational cancer research.

He specializes in target identification and validation for antibody therapy in cancer.

NOTES

rAAVen
THERAPEUTICS

rAAVen Therapeutics

rAAVen Therapeutics is a Swedish biotech company designing next-generation gene therapy vectors. Its platform generates and screens barcoded AAV capsid libraries, leveraging rational peptide design and high-throughput sequencing to discover novel capsids with precise tissue targeting.

By optimizing viral vectors for specific cell populations and functional properties, rAAVen provides tailored delivery solutions for diverse genetic diseases. The company collaborates with pharmaceutical partners to supply engineered capsids that improve the safety and efficacy of in vivo gene therapies.

www.raaven.se

FIELD

Pharmaceuticals,
Biotechnology

DATE OF INCORPORATION

2022

STOCK MARKET LISTING

No

MATURITY

Preclinical

PRODUCT ON THE MARKET?

Yes

AMOUNT THEY WISH TO RAISE WITH MVIP

4 MEuros

HOW THEY INTEND TO USE THE FUNDS RAISED

Funds will accelerate the development of rAAVen's proprietary pipeline while advancing selected capsids toward strategic partnering and licensing opportunities



Marcus Davidsson, PhD

CEO

Marcus Davidsson, PhD, is the founder and CEO of rAAVen Therapeutics. He earned his PhD in Neuroscience from Lund University and completed postdoctoral research at Michigan State University and the Barrow Neurological Institute.

Over the past decade Marcus has specialized in adeno-associated virus (AAV) engineering, developing DNA barcoding methods and custom capsid libraries for gene therapy. He founded rAAVen to translate this expertise into new viral vectors. Marcus leads the team's scientific strategy and partnerships to integrate rAAVen's vectors into next-generation gene therapies.

marcus.davidsson@raaven.se



Patrick Aldrin-Kirk, PhD

Chief Scientific Officer

Patrick Aldrin-Kirk completed his PhD in Neurobiology at Lund University, where his research included AAV capsid engineering and neural circuit applications. He subsequently conducted postdoctoral research at the University of Copenhagen and later became Assistant Professor, working on advanced neural and stem-cell models.

As CSO of rAAVen Therapeutics, he leads the company's scientific strategy and development of engineered AAV capsids.

NOTES



Xaga Surgical

Xaga Surgical is a Swedish medtech company that has redesigned the prostate biopsy needle, unchanged since 1969. The Forsvall Biopsy System delivers improved targeting, better biopsies with significantly longer tissue cores for the pathologist, and 96% less bacterial transfer – addressing the root cause of post-biopsy infection.

FDA 510(k) cleared and generating revenue in the US, with CE marking imminent and European centers waiting. Prostate biopsy is the first indication of many in soft tissue biopsy.

xagasurgical.com

FIELD

Medtech

PRODUCT ON THE MARKET?

Yes

DATE OF INCORPORATION

2016

AMOUNT THEY WISH TO RAISE WITH MVIP

5 MEuros

STOCK MARKET LISTING

No

HOW THEY INTEND TO USE THE FUNDS RAISED

Scale the commercial organization in the US and Europe, run three clinical studies aimed at guideline change, industrialize production and broaden the product portfolio

MATURITY

Commercial stage



Andreas Forsvall, MD PhD

CEO

Founder and CEO of Xaga Surgical and a practicing urologist with over 15 years of surgical experience. He designed the Forsvall Biopsy System after seeing post-biopsy infections in his own patients and has taken it from bench to FDA 510(k) clearance and first revenue.

He leads Xaga's clinical program, product strategy and commercial build-out in the US and Europe.

andreasforsvall@xagasurgical.com



Martin Ekenbäck

COO

COO of Xaga Surgical since 2024. He brings leadership experience from Swedish startups and scale-ups: COO at Hemma, Head of Sales and Customer Success at Tink (acquired by Visa in 2021) and Partner & Commercial Director at Nepa (IPO 2016), with an earlier background as Senior Associate at McKinsey & Company. At Xaga he runs operations, production and sourcing.

martinekenback@xagasurgical.com

NOTES



Bengt Julander
Chairman at Linc



Bengt Julander is the Chairman and founder of the publicly listed investment company Linc, considered one of Sweden's most renowned investors in Life Science. He has had a long career in the pharmaceutical industry and co-founded Calliditas Therapeutics – a company recently sold for approximately SEK 12 billion.

Under Julander's leadership, Linc has built a strong portfolio of life science companies. He is known for his deep industry knowledge and successful investments that drive the development of new treatments.

bengt.julander@linc.se



Erika Wallace
Executive Director and Head of
Innovation Economy EMEA at
J.P. Morgan Private Bank



Erika Wallace is an Executive Director and Head of Innovation Economy EMEA at J.P. Morgan Private Bank. She works closely with technology founders, venture capital funds and LPs across the broader startup ecosystem, with a particular focus on the founder journey and liquidity events. Erika is actively involved in building founder communities through network-driven initiatives and partnerships, including Global collaborations with Endeavor and cross-platform engagement within J.P. Morgan's Innovation Economy teams.

Her focus is centered on the innovation economy, spanning entrepreneurs, startups and the VC landscape, rather than a proprietary investment mandate. She brings a highly connected, platform-driven approach, linking founders and investors to global institutional capital and expertise.

erika.b.wallace@jpmorgan.com

**Jonathan P. Gertler**

Co-Founder, Managing Partner
and CEO of Back Bay Life Science
Advisors



Jonathan P. Gertler, MD, is Co-Founder, Managing Partner and CEO of Back Bay Life Science Advisors, an integrated strategy and investment banking firm based in Boston, Massachusetts, with strong ties to the Nordic regions. A former academic vascular surgeon who studied at Columbia and trained at Yale and Massachusetts General Hospital, Dr. Gertler has more than 35 years of clinical and scientific expertise with extensive advisory work in private and public equity and M&A for biotech, medtech and healthcare IT companies. He is a current partner at BioVentures MedTech Funds and part of the founding team at DNB Carnegie Back Bay Healthcare.

JGertler@bblsa.com

**Bitia Sehat**

Partner at Trill Impact



Bitia Sehat is a Partner at Trill Impact and a life sciences investor with more than 20 years of experience spanning scientific research, venture capital and company building. She invests in and works with companies at the intersection of science, technology and healthcare, with a particular interest in how emerging technologies are reshaping life sciences.

Before joining Trill Impact, Bitia was Investment Director at Industrifonden. Earlier, she worked across healthcare investing, strategy and business development in Europe and North America, following nearly a decade in academic cancer research.

Bitia holds a PhD in Molecular Oncology from Karolinska Institutet, completed postdoctoral research at Karolinska Institutet and McGill University, and holds an MBA from Concordia University. She serves on several boards and advisory bodies.

bita.sehat@trillimpact.com

**Markus Dietrich**

Senior Investment Associate
at Hadean Ventures



Markus Dietrich holds a PhD in Oncology and is a Senior Investment Associate at Hadean Ventures, a leading European life sciences venture capital firm with a strong focus on the Nordic region. Hadean Ventures invests across the life science spectrum, including specialty pharmaceuticals, medical technology, diagnostics, and digital health, and operates from offices in Oslo and Stockholm.

Markus has been involved in notable exit investments such as Cardior and Emergence Therapeutics and currently serves in board roles at Oncoinvent and Arthex. He also holds an MBA from Imperial College Business School, bringing together deep scientific expertise with strategy and investment.

markus.dietrich@hadeanventures.com

**Shamim Dadvar**

Associate at HealthCap



Shamim Dadvar is an Associate at HealthCap, working within the firm's global life sciences venture platform. She combines a clinical background in orthopedic surgery with research experience in molecular metabolism and cellular bioenergetics. Shamim completed her medical training at Karolinska Institutet and Northwestern University and holds a PhD alongside her MD.


She also has entrepreneurial experience, having co-founded and led the scientific division of a consumer-facing laboratory testing platform in Chicago that was acquired in 2021. She brings a strong ability to assess clinical relevance, scientific rationale and execution pathways, bridging medicine and venture investing.

shamim.dadvar@healthcap.eu

**Emilia Carlqvist**Investment Analyst at
Innovestor**≥ INNOVESTOR**

Emilia Carlqvist is an Investment Analyst in Innovestor's Life Science team, focusing on early-stage investments in biotech and digital health across the Nordics and Baltics, from pre-seed to Series A. Prior to joining venture capital, she built a clinical career across multiple specialties, with a particular focus on emergency medicine. She has a combined background as a medical doctor and an economist, providing a dual perspective on clinical relevance and value creation.

Emilia focuses on companies addressing unmet medical needs with global scalability and brings a clinically grounded, analytically driven approach to evaluating healthcare innovation.

emilia.carlqvist@innovestor.fi**Karin Leire**Investment Director at Segulah
Medical Acceleration

Karin Leire is an Investment Director at Segulah Medical, where she focuses on investments and growth initiatives within the life sciences sector. She brings extensive experience from clinical research, innovation management and operational leadership, including senior roles in medtech and pharmaceutical development.

Karin has worked across both industry and research environments, supporting companies in scaling innovation, advancing clinical development and building strategic partnerships.

leire@segulahmedical.com

**Jonas Jendi**

Chief Operating Officer and
Senior Investment Director
at Industrifonden

Industrifonden

Jonas is Chief Operating Officer and Senior Investment Director at Industrifonden, where he focuses on life sciences and supports the investment process across the fund. He has more than 20 years of experience spanning entrepreneurship, start-ups, venture investing and business development. Prior to joining Industrifonden in 2017, Jonas was CEO of Cogmed, where he spent more than 10 years developing the company in the cognitive training sector, launching its business in the US and integrating it into a global enterprise following its exit. His previous experience also includes chairman and board roles, advisory and co-founder positions across listed biotech, mental health, edtech, semiconductors and investment banking.

Jonas began his career in the start-up sector during the dot-com era and has since worked extensively with early-stage companies and radical innovations. At Industrifonden, his life science focus has included medical devices, medical nutrition, cancer diagnostics and cell reprogramming. He holds an M.Sc. from the Stockholm School of Economics.

jonas.jendi@industrifonden.com



Arvid Söderhäll
Venture Partner at Flerie

FLERIE

Arvid Söderhäll is a Venture Partner at Flerie, where he works closely with portfolio companies across strategy, product and drug development, and scientific evaluation within the life sciences sector. With a PhD in physical chemistry and broad experience across pharmaceutical development, Arvid combines deep scientific expertise with extensive experience in translational research and biotech innovation.

He has contributed to the development and advancement of multiple therapeutic platforms and brings a research-driven perspective to venture investments, supporting entrepreneurs and emerging companies in transforming scientific discoveries into scalable healthcare solutions.

arvid@flerie.com

MVIP

Following a successful inaugural edition in 2025, MVIP returns for its second edition in 2026 and will continue as a recurring initiative at Medicon Village.

If you are a company or investor interested in participating in future editions, please do not hesitate to contact Sarah Lidé (sarah.lide@mediconvillage.se) or Francesco Bez (francesco.bez@mediconvillage.se).

STRATEGIC CAPITAL.
EXPERT GUIDANCE.
LIFE-CHANGING LIFE SCIENCE.

